Fred Hutch statement regarding FDA action on CTL019 immunotherapy – Fred Hutch News Service
Fred Hutch News Service |
Fred Hutch statement regarding FDA action on CTL019 immunotherapy
Fred Hutch News Service SEATTLE — AUG. 30, 2017 — Today the U.S. Food and Drug Administration approved the use of a new Novartis immunotherapy drug, CTL019, as a treatment for advanced leukemia in children and young adults. This latest FDA ruling validates the … New 'hit-and-run' gene editing tool temporarily rewrites genetics to treat cancer and HIV |
